Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INV-101 · 1 trial · 1 indication
Cmax following single dose
AUC following single dose
Half-live following single dose
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 20 mg INV-101 |
| Cohort 2 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 80 mg INV-101 |
| Cohort 3 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 160 mg INV-101 |
| Cohort 4 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 320 mg INV-101 |
| Cohort 5 | EXPERIMENTAL | Subjects will be randomized to receive either placebo or 500 mg INV-101 |
| Name | Type | Description |
|---|---|---|
| INV-101 | DRUG | Subjects will be randomized to receive INV-101 tablets |
| Placebo | DRUG | Subjects will be randomized to receive placebo tablets |
Inclusion Criteria: * Healthy adult male or female * Body mass index (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively; and body weight ≥60 kg * Non- or ex-smoker * Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physica...
INV-101 is an investigational small molecule being developed by Novo Nordisk A/S (NVO). It is currently in Phase 1 clinical development. The drug is being studied for its pharmacokinetic properties, meaning how the body absorbs, distributes, metabolizes, and excretes the drug.
INV-101 is being studied for pharmacokinetic purposes, which involves understanding how the drug behaves in the body. It is not being developed for a specific disease indication at this stage. The drug is in early clinical development to assess its safety, tolerability, and pharmacokinetics in healthy subjects.
INV-101 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the drug's safety, tolerability, and pharmacokinetics in healthy volunteers.
INV-101 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It is being studied in early-stage clinical trials to evaluate its safety, tolerability, and pharmacokinetic profile in healthy subjects.
INV-101 has one completed clinical trial, identified as NCT04531150. This was a Phase 1 study titled "Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects." The trial enrolled 40 participants in Canada and was a randomized, double-blind, controlled study.
INV-101 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied in clinical trials to evaluate its safety, tolerability, and pharmacokinetics, but it has not yet received regulatory approval for any use.